The agreement enables SOTIO to license multiple fully human bispecific antibodies from Biocytogen’s RenLite platform.
SOTIO Biotech, Biocytogen Ink Research and License Agreement to Develop Next-Generation Antibody-Drug Conjugates
The agreement enables SOTIO to license multiple fully human bispecific antibodies from Biocytogen’s RenLite platform.